BD (NYSE:BDX) announced that it entered into a worldwide commercial collaboration agreement with Accelerate Diagnostics (Nasdaq:AXDX).
Under the agreement announced earlier this week, BD will offer Accelerate’s rapid testing solution for antibiotic resistance and susceptibility, with results offered in hours compared to between one and two days with some traditional laboratory methods.
Anti-biotic-resistant infections have been on the rise for years. In 2016, details released from the 2014 Review on Antimicrobial Resistance (AMR), commissioned by the UK government to address the concern that superbugs, resistant to current antibiotics, could eventually evolve to the point that the drugs are no longer effective.
In 2020, more than 20 biopharmaceutical companies around the world pledged more than $1 billion toward the Antimicrobial Resistance (AMR) Action Fund.
Under the agreement between BD and Accelerate, BD will market the Accelerate Pheno …